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ABSTRACT
Question
What is the optimal chemotherapy treatment for
women with recurrent ovarian cancer who have pre-
viously received platinum-based chemotherapy?
Perspectives
Currently, standard primary therapy for advanced
disease involves a combination of maximal
cytoreductive surgery and chemotherapy with
carboplatin plus paclitaxel or with carboplatin alone.
Despite initial high response rates, a large propor-
tion of patients relapse, resulting in a therapeutic chal-
lenge. Because these patients are not curable, the goal
of therapy becomes improvement in both quality and
length of life. The search has therefore been to find
active agents for women with recurrent disease fol-
lowing platinum-based chemotherapy.
Outcomes
Outcomes of interest included any combination of
tumour response rate, progression-free survival, over-
all survival, adverse events, and quality of life.
Methodology
The MEDLINE, EMBASE, and Cochrane Library databases
were systematically searched for primary articles and
practice guidelines. The resulting evidence informed
the development of clinical practice recommenda-
tions. The systematic review and recommendations
were approved by the Report Approval Panel of the
Program in Evidence-Based Care, and by the Gyne-
cology Cancer Disease Site Group (DSG). The prac-
tice guideline was externally reviewed by a sample
of practitioners from Ontario, Canada.
Results
Thirteen randomized trials compared various chemo-
therapy regimens for patients with recurrent ovarian
cancer.
In five of the thirteen trials in which 100% of
patients were considered sensitive to platinum-con-
taining chemotherapy, further platinum-based com-
bination chemotherapy significantly improved
response rates (two trials), progression-free survival
(four trials), and overall survival (three trials) when
compared with single-agent chemotherapy involving
carboplatin or paclitaxel. Only two of these random-
ized trials compared the same chemotherapy regi-
mens: carboplatin alone versus the combination of
carboplatin and paclitaxel. Both trials were consis-
tent in reporting improved survival outcomes with
the combination of carboplatin and paclitaxel. In one
trial, the combination of carboplatin and gemcitabine
resulted in significantly higher response rates and im-
proved progression-free survival when compared
with carboplatin alone. Median survival with carbo-
platin alone ranged from 17 months to 24 months in
four trials.
In eight of the thirteen trials in which 35%–100%
of patients had platinum-refractory or -resistant dis-
ease, one trial reported a statistically significant
Optimal chemotherapy
treatment for women with
recurrent ovarian cancer
M. Fung-Kee-Fung MD,* T. Oliver BA,†
L. Elit MD,‡ A. Oza MD,§ H.W. Hirte MD,‡ and
P. Bryson MD§|| on behalf of the Gynecology
Cancer Disease Site Group# of Cancer Care
Ontario’s Program in Evidence-Based Care
PRACTICE GUIDELINE SERIES
Cancer Care Ontario’s Program in Evidence-Based
Care is sponsored by Cancer Care Ontario and
the Ontario Ministry of Health and Long-Term Care.
Copyright © 2007 Multimed Inc.FUNG-KEE-FUNG et al.
196
CURRENT ONCOLOGY—VOLUME 14, NUMBER 5
2-month improvement in overall survival with lipo-
somal doxorubicin as compared with topotecan
(15 months vs. 13 months, p = 0.038; hazard ratio:
1.23; 95% confidence interval: 1.01 to 1.50). In that
trial, because of the limited clinical benefit and the
unusual finding that a survival difference emerged
only after a year of treatment with no corresponding
improvement in the rate of response or of progres-
sion-free survival, the authors concluded that further
confirmation by results from randomized trials were
needed to establish the superiority of one agent over
another in their trial. In one trial, topotecan was su-
perior to treosulphan in patient progression-free sur-
vival by a span of approximately 2 months
(5.4 months vs. 3.0 months, p < 0.001).
Toxicity was reported in all of the randomized
trials, and although data on adverse events varied by
treatment regimen, the observed adverse events cor-
related with known toxicity profiles. As expected,
combination chemotherapy was associated with
higher rates of adverse events.
Practice Guideline
Target Population This clinical recommendation ap-
plies to women with recurrent epithelial ovarian can-
cer who have previously received platinum-based
chemotherapy. Of specific interest are women who
have previously shown sensitivity to platinum therapy
and those who previously were refractory or resis-
tant to platinum-based chemotherapy. As a general
categorization within what is actually a continuum,
“platinum sensitivity” refers to disease recurrence
6 months or more after prior platinum-containing
chemotherapy, and “platinum resistance” refers to a
response to platinum-based chemotherapy followed
by relapse less than 6 months after chemotherapy is
stopped. “Platinum-refractory disease” refers to a lack
of response or to progression while on platinum-based
chemotherapy.
Recommendations Although the body of evidence
that informs the clinical recommendations is based
on randomized trial data, those data are incomplete.
Based on the available data and expert consensus
opinion, the Gynecology Cancer DSG makes these
recommendations:
• Systemic therapy for recurrent ovarian cancer is
not curative. It is therefore recognized that each
patient must be individually assessed to determine
optimal therapy in terms of recurrence, sensitiv-
ity to platinum, toxicity, ease of administration,
and patient preference. All suitable patients should
be offered the opportunity to participate in ran-
domized trials, if available.
• In the absence of contraindications, combination
platinum-based chemotherapy should be consid-
ered for patients with prior sensitivity to plati-
num-containing chemotherapy. As compared
with carboplatin alone, the combination of
carboplatin and paclitaxel significantly improved
both progression-free and overall survival.
• If combination platinum-based chemotherapy is
not indicated, then a single platinum agent should
be considered. Carboplatin has demonstrated ef-
ficacy across trials and has a manageable toxic-
ity profile.
• If a single platinum agent is not being consid-
ered, then monotherapy with paclitaxel, topote-
can, or pegylated liposomal doxorubicin are seen
as reasonable treatment options.
• Some patients may be repeatedly sensitive to
treatment and may benefit from multiple lines of
chemotherapy.
• For patients with platinum-refractory or platinum-
resistant disease, the goals of treatment should
be to improve quality of life by extending the
symptom-free interval, by reducing symptom in-
tensity, and by increasing progression-free inter-
val, and, if possible, to prolong life.
• With non-platinum agents, monotherapy should
be considered because no advantage appears to
accrue to the use of non-platinum-containing
combination chemotherapy in this group of pa-
tients. Single-agent paclitaxel, topotecan, or
pegylated liposomal doxorubicin have demon-
strated activity in this patient population and are
reasonable treatment options.
• No evidence either supports or refutes the use of
more than one line of chemotherapy in patients
with platinum-refractory or platinum-resistant re-
currence. Many treatment options have shown
modest response rates, but their benefits over best
supportive care have not been studied in clinical
trials.
KEY WORDS
Chemotherapy, drug therapy, ovarian cancer, ovarian
neoplasms, practice guideline, systematic review
1. QUESTION
What is the optimal chemotherapy treatment for
women with recurrent ovarian cancer who have pre-
viously received platinum-based chemotherapy?
2. CHOICE OF TOPIC AND RATIONALE
In Canada, ovarian cancer is the fifth leading cause
of cancer death among women and the leading cause
of gynecologic cancer mortality 1. Estimates suggest
that approximately 2400 new cases of ovarian can-
cer and 1550 deaths from the disease occurred in
2005, for a mortality-to-incidence ratio of 0.66 1.
Currently, standard primary therapy for advanced
disease involves the combination of maximal cyto-
reductive surgery and chemotherapy with carboplatinPRACTICE GUIDELINE SERIES
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plus paclitaxel or with carboplatin alone 2,3. Despite
high initial response rates, a large proportion of pa-
tients relapse 4, resulting in a therapeutic challenge.
Because these patients are not curable 5, the goal of
therapy becomes improvement in both quality and
length of life. The willingness of patients to undergo
aggressive therapies for modest gains is growing, as
has been documented for some other disease sites 6.
This attitude has added a further dimension to the
question of optimal treatment choice in this setting.
The search has therefore been for active agents in
women with recurrent disease after platinum-based
chemotherapy.
One of the most frequently documented clinical
surrogates for predicting response to chemotherapy
in women with recurrent ovarian cancer has been the
“platinum-free interval”—that is, the period of time
from cessation of primary platinum-based chemo-
therapy to disease recurrence. Described in terms of
platinum resistance or sensitivity, “responsiveness”
is best characterized as a continuum. Increasing sen-
sitivity to platinum is positively correlated with time
from initial treatment to recurrence, such that dis-
ease that recurs more than 2 years after primary che-
motherapy has a response rate to re-treatment with
platinum approaching that associated with primary
chemotherapy 7.
Before a patient is treated with platinum-based
chemotherapy, it is impossible to assess whether she
will or will not be sensitive to platinum. In addition,
cancer in individual patients becomes increasingly
resistant to platinum over time. However, the rate at
which resistance develops is variable, and thus some
women respond to multiple lines of platinum-based
chemotherapy and some respond not at all.
Women with platinum-resistant disease have uni-
formly low response rates to chemotherapy. Further
complicating the decision of what to offer these pa-
tients is the wide range of approaches to treatment
among specialists dealing with this dilemma. The
options range from using less toxic treatments as
therapy for symptomatic disease, including single-
agent chemotherapy or best supportive care, to using
a range of multi-agent regimens in aggressive therapy
for asymptomatic patients.
Generally, the disease can be defined as “plati-
num-resistant” if recurrence is diagnosed less than
6 months after platinum-based chemotherapy has
been completed. “Platinum-sensitive” disease can be
defined as recurrence 6 months or more after the end
of platinum-based chemotherapy. Although these
definitions are somewhat arbitrary (because platinum
sensitivity should be regarded more as a continuum),
the decision to establish a 6-month cut-off for defin-
ing platinum resistance and sensitivity is supported
by the outcomes from other studies of platinum-pre-
treated patients with ovarian cancer 8,9.
The present review of the evidence focuses on
systemic chemotherapy; it does not evaluate intra-
peritoneal chemotherapy, hormonal therapy, or che-
motherapy with bone marrow or stem-cell transplan-
tation. The role of hormonal therapy in the treatment
of recurrent ovarian cancer, although limited, is ac-
knowledged to have been well addressed in published
reviews 10,11. The present review summarizes the best
available evidence on the optimal use of various che-
motherapeutic agents in the treatment of platinum-
sensitive and platinum-resistant recurrent ovarian
cancer.
3. METHODS
3.1 Guideline Development
The present systematic review of the evidence was
developed by Cancer Care Ontario’s Program in Evi-
dence-Based Care (PEBC) using the methods of the
practice guidelines development cycle 12. Evidence
was selected and extracted by one member of the
PEBC’s Gynecology Cancer Disease Site Group (DSG)
and by a methodologist. All drafts of the text were
reviewed, modified, and approved by the Gynecol-
ogy Cancer DSG, and also by a Report Approval Panel
(RAP) of the PEBC.
This review is a convenient and up-to-date source
of the best available evidence on chemotherapy in
the treatment of women with recurrent epithelial ova-
rian cancer. The body of evidence upon which the
review is based primarily comprises data from ran-
domized controlled trials (RCTs). The systematic re-
view and companion practice guideline developed
by the Gynecology Cancer DSG are intended to pro-
mote evidence-based practice in Ontario, Canada.
The PEBC is editorially independent of Cancer Care
Ontario and the Ontario Ministry of Health and Long-
Term Care.
An evidence summary on the management of
women with recurrent ovarian cancer was originally
completed in 2001 by the Gynecology Cancer DSG 13.
The present document replaces the 2001 report.
3.2 Literature Search Strategy
The MEDLINE (OVID: 1966 through March 2006),
EMBASE (OVID: 1988 through March 2006), Cochrane
Library (OVID: Issue 1, 2006), the Canadian Medical
Association Infobase, and the National Guidelines
Clearinghouse were systematically searched for evi-
dence relevant to this report. In addition, the abstracts
published in the proceedings of the meetings of the
American Society of Clinical Oncology (1997–2005)
and the European Society for Medical Oncology
(2002, 2004) were similarly searched. Reference lists
of related papers and recent review articles were
scanned for additional citations.
Searches of electronic databases combined the
terms (ovarian neoplasms/ or ovarian.ti. and
neoplasm:.mp. or cancer.mp.) with (neoplasm recur-FUNG-KEE-FUNG et al.
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rence local/ or neoplasm metastasis/ or recurren:.mp.
or relapse:.mp. or resistance.mp.) and (drug therapy/
or antineoplastic agents/ or chemotherapy.mp.) for
these study designs: RCTs, meta-analyses, practice
guidelines, and systematic reviews.
3.3 Study Selection Criteria
Articles were selected for inclusion in this system-
atic review of the evidence if they were RCTs that
compared chemotherapeutic agents as part of sec-
ond- or greater-line treatment for patients with re-
current epithelial ovarian cancer who had previously
been treated with platinum-containing chemotherapy,
and if they reported data on at least one of the fol-
lowing outcomes of interest: overall survival, pro-
gression-free survival, tumour response rate, adverse
events, or quality of life (QOL).
Practice guidelines, meta-analyses, or systematic
reviews explicitly based on randomized trials related
to the guideline question were also eligible for in-
clusion in the systematic review of the evidence.
Articles were excluded from the systematic re-
view of the evidence if they were written in a lan-
guage other than English or if they included the use
of intraperitoneal chemotherapy, hormonal therapy,
or chemotherapy with bone marrow or stem-cell
transplantation.
4. RESULTS
4.1 Literature Search Results
Thirteen randomized trials comparing various che-
motherapy regimens for women with recurrent ova-
rian cancer were identified and deemed eligible for
inclusion in the systematic review of the evi-
dence 14–26. In the event of multiple publications per
trial, only the most recent publication was cited. Ten
trials were fully published 14–18,20,22–24,26, and three
trials were reported as abstracts from conference pro-
ceedings 19,21,25. Table I presents the literature search
results and select trial characteristics.
4.2 Trial Characteristics
To be eligible to participate in the randomized trials,
patients had to have recurrent ovarian cancer after
prior first-line 14,16–18,21–23,25,26 or prior first- or sec-
ond-line treatment 15,19,20,24 with platinum-containing
chemotherapy. Where reported, patients were strati-
fied by age 18,20, presence of ascites 18, type of prior
chemotherapy 14,20, chemotherapy-free interval 20,24,
number of lines of treatment 20,24, bi-dimensionally
measurable disease 14, performance status 20,24, plati-
num-free interval 14,16–18,20,21, presence of bulky dis-
ease exceeding 5 cm 17,21, or treatment center 16,20,24.
The median age of the patients ranged from a low
of 54 years to a high of 61 years 14–18,20–24. Eight tri-
als included patients over the age of 70 years 14–18,
21,23,24, and four trials included patients who were
more than 80 years of age 14,17,18,24. With the excep-
tion of one trial 18, information on patient height,
weight, body mass index, or menopausal status was
not reported. In the one trial that reported those data 18,
the mean weight of the patients was approximately
66 kg, and the mean body surface was 1.7 m2.
As can be seen in Table I, various chemothera-
peutic regimens were investigated across the thirteen
trials. Carboplatin, paclitaxel, and topotecan were the
most commonly used agents, however only two of
the thirteen trials compared similar regimens: single-
agent carboplatin versus combination carboplatin and
paclitaxel 15,20. In the larger of the latter two trials 20,
196 patients (24%) received chemotherapy other than
carboplatin alone or the combination of carboplatin
and paclitaxel.
Treatment schedules varied across the trials, with
the scheduled cycles of chemotherapy ranging from
a low of 4 to a high of 12 14–18,20–26. One trial did not
report information about cycles 19, and in one trial 24,
treatment was intended to continue until progression,
undue toxicity, or patient refusal.
In eight trials 14–16,20,22,23,25,26, patients were ran-
domized to either single-agent or multi-agent che-
motherapy, and in five randomized trials, single-agent
chemotherapy was compared with other single-agent
chemotherapy 17–19,21,24.
In five trials, only patients who responded for
more than 6 months 14,15,20,22,23 after first-line treat-
ment with a platinum-containing regimen (consid-
ered “platinum-sensitive”) were eligible to participate
in the randomized studies. In four of those trials, plati-
num sensitivity was demonstrated beyond a 12-month
period in approximately 60% 14,15,20 or 100% 22 of
patients. In the remaining study, data on the persis-
tence of platinum-sensitivity were not reported 23. In
four of the five trials, second- or third-line treatment
contained further platinum-containing chemotherapy;
the one exception was a small study in which
paclitaxel was used in one of the treatment arms 22.
In eight studies 16–19,21,23,24,25, 35%–100% of pa-
tients experienced progression less than 6 months
after treatment with a platinum-containing regimen.
Those patients were considered platinum-refractory
or platinum-resistant. In seven of these eight studies
of partial 16–19,21,24,25 or complete platinum-resis-
tance 26, non-platinum-containing regimens were in-
vestigated. Again, the one exception was one small
study in which oxaliplatin was used in one of the
treatment arms 24.
In five of the trials that included patients with
both platinum-sensitive and platinum-resistant dis-
ease 16–18,21,24, results were also reported separately
for the two subgroups of patients.
Protocols for treatment modification included
cycle delay 15–17,22–24, dose reduction 15–18,23,24,26, and
use of erythropoietin 14 or granulocyte colony–stimu-PRACTICE GUIDELINE SERIES
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lating factor 14,17,18,23,26. Where reported, patients were
removed from the study if treatment delay was greater
than 2 18 or 6 weeks 15, if adverse events occurred 15,17,
18,24, or if dose reductions fell below the minimum
allowable dose 24. Patient crossover to the alterna-
tive agent, considered third-line chemotherapy, was
allowed in two trials 18,22 and was not reported in the
remaining trials 14–17,19–21,23–26.
The primary study endpoints were reported to be
various combinations of response rate 15,18,23–26, du-
TABLE I Literature search results and selected trial characteristics
Reference Patients Agent Treatment regimen Platinum-sensitive CT
(n) Dose Day Cycles patients (%) line
(planned) <6 mo. ³6 mo.
Pfisterer et al., 2005 14 178 Carboplatin AUC=5 1 6 0 100 a 2
NCIC OV15 178 Carboplatin/ AUC=4 1 6 0 100 a 2
gemcitabine 1000 mg/m2 1+8 6
Gonzalez–Martin et al., 2005 15 40 Carboplatin AUC=5 1 6–9 0 100 a 2–3
GEICO 41 Carboplatin/ AUC=5 1 6–9 0 100 a 2–3
paclitaxel 175 mg/m2 1 6–9
Buda et al., 2004 16 106 Paclitaxel 175 mg/m2 1 4–6 75 25 2
GONO/IOR 106 Paclitaxel/ 175 mg/m2 1 4–6 73 27 2
epirubicin 80 mg/m2 1 4–6
Gordon et al., 2004 17 239 Pegylated doxorubicin 50 mg/m2 11 2 5 4 4 62
Doxil 30-49 235 topotecan 1.5 mg/m2 1–5 12 53 47 2
ten Bokkel Huinink et al., 2004 18 112 Paclitaxel 175 mg/m2 11 2 5 2 4 82
ITSG 114 Topotecan 1.5 mg/m2 1–5 12 54 46 2
Meier et al., 2004 19,b 179 Treosulfan 7.0 g/m2 NR NR 36 64 2–3
AGO 178 Topotecan 1.5 mg/m2 1–5 NR 34 66 2–3
Parmar et al., 2003 20 410 Carboplatin c AUC³5 1 6–8 0 100 a 2 d
ICON4/AGO 392 Carboplatin/ AUC³5 1 6–8 0 100 a 2 d
paclitaxel c ³175 mg/m2 1 6–8
O’Byrne et al., 2002 21,b 107 Pegylated 50 mg/m2 1 NR 60 40 2
doxorubicin
107 Paclitaxel 175 mg/m2 1 NR 63 37 2
Cantu et al., 2002 22 50 Paclitaxel 175 mg/m2 1 ³6 0 100 e 2
47 Cyclophosphamide/ 500 mg/m2 1 ³6 0 100 e 2
doxorubicin/ 50 mg/m2 1 ³6
cisplatin 50 mg/m2 1 ³6
Bolis et al., 2001 23 95 Carboplatin 300 mg/m2 1 5 0 100 2
95 Carboplatin/ 300 mg/m2 1 5 0 100 2
epirubicin 120 mg/m2 15
Piccart et al., 2000 24 41 Paclitaxel 175 mg/m2 16  f 76 24 2–3
45 Oxaliplatin 130 mg/m2 14  f 71 29 2–3
Torri et al., 2000 25,b 116 Paclitaxel 175 mg/m2 1 4–6 ³50 g £50 g 2
118 Paclitaxel/ 175 mg/m2 1 4–6 ³50 g £50 g 2
doxorubicin 80 mg/m2 1 4–6
Bolis et al., 1999 26 41 Paclitaxel 175 mg/m2 1 5 100 0 2
40 Paclitaxel/ 150 mg/m2 1 5 100 0 2
epirubicin 120 mg/m2 15
a Approximately 60% of patients were platinum-sensitive beyond 12 months.
b Abstract data from conference proceedings.
c The authors reported that 24% of patients received chemotherapy other than carboplatin or paclitaxel and carboplatin.
d Among these patients, 8% received third- or greater-line chemotherapy.
e In this trial, 100% of patients were platinum-sensitive beyond 12 months.
f Actual median number of cycles delivered.
g Median time from the end of first-line chemotherapy to trial randomization was 5 months, with a range of 3–12 months.
CT = chemotherapy; NCIC OV15 = National Cancer Institute of Canada OV15 trial; AUC = area under curve; GEICO = Grupo Espanol de Investigacion
en Cancer de Ovario; GONO/IOR = Gruppo Oncologico Nord Ovest/Istituto Oncologico Romagnolo; Doxil 30-49 = Doxil Study 30-49; ITSG =
International Topotecan Study Group; AGO = Arbeitsgemeinschaft Gynaekologische Onkologie.FUNG-KEE-FUNG et al.
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ration of response 18, progression-free survival 14,17,
18,21, toxicity 23, and overall survival 16,17,19–22.
Seven trials reported QOL as a study end-
point 14,15,17–20,24. Assessment of QOL used the Euro-
pean Organization for Research on Cancer treatment
QOL questionnaire 14,15,17,18,20,24, including the ovarian
cancer module 14, and a “specific checklist” that was
not fully described 24. One trial reported as an ab-
stract did not provide details on QOL assessment or
on QOL results between treatment groups 19. The re-
maining trials did not report whether data on QOL were
collected 16,21–23,25,26.
Overall, in assessing the characteristics of the thir-
teen randomized trials, it was clear that the eligible
trials varied widely, making it difficult to compare
results across trials. Important differences in platinum
sensitivity, type of chemotherapy, number of agents
employed, cycles of chemotherapy, and study end-
points all contributed to inter-trial heterogeneity.
4.3 Trial Quality
The identified trials were non-blinded multi-
centre 14,16–26 or single-centre 15 phase III 14,16–21,23,25,26
or phase II RCTs 15,22,24. In seven trials, the random-
ization procedure was reported 15,16,18,20,23,24,26; the
remaining trials did not report that informa-
tion 14,17,19,21,22,25. Eight trials reported patient accrual
with sufficient power to detect significant differences
between treatment groups 14–17,20,22,23,26 at an alpha
level of 0.05 15,16,20,22,23,26. Five trials did not report
information on power calculations 18,19,21,24,25. One
phase II trial employed a “pick the winner design”
that was sufficiently powered; however, given the
small number of patients involved, a formal statisti-
cal comparison between treatment arms was not
planned. That trial eventually reported statistical com-
parisons of primary and secondary endpoints as part
of exploratory analyses 15.
Baseline characteristics were reported or ob-
served to be generally similar across treatment groups
in twelve trials 14–24,26; they were not reported in one
trial 25. Statistical comparisons between baseline char-
acteristics of the patients were reported in two trials,
with no statistically significant differences being de-
tected between treatment groups 15,21.
Across eleven trials, completeness of follow-up
was reported or inferred to be greater than 80% 14–18,
20–24,26, and in two trials data on follow-up were not
available 19,25. Eight trials reported data using the in-
tent-to-treat principle 15–18,20,22,23,26. In three tri-
als 14,21,24 where intent-to-treat information was not
explicitly reported, it could be inferred from the pub-
lished trial data.
In general, the methodologic quality of the tri-
als—that is, their internal validity—was deemed to
be sufficient to permit meaningful conclusions to be
drawn from the results of the individual trials (exter-
nal validity).
4.4 Outcomes
Table II shows response and survival results for the
thirteen randomized trials identified in the review of
the evidence.
4.4.1 Survival
Survival data were reported 14–22,24,25 or extracted
from survival curves 23,26 for all of the randomized
trials. Survival was reported to be a primary study
endpoint in six of the thirteen trials 16,17,19–22.
As Table II shows, four trials detected significant
differences in survival between treatment groups 15,17,
20,22. In three trials of these trials (with 100% of the
patients being platinum-sensitive), significant sur-
vival advantages were detected with combination
platinum-containing chemotherapy as compared with
single-agent chemotherapy 15,20,22. In the remaining
trial (with a mixed platinum-sensitive and platinum-
resistant patient population) 17, a statistically signifi-
cant median survival advantage of 2 months was
detected with liposomal doxorubicin as compared
with topotecan. In that trial, no significant differences
were observed in response rate or progression-free
survival, and the survival curves for the treatment
arms were virtually indistinguishable for approxi-
mately the first year. Shortly beyond year 1, the sur-
vival curve for liposomal doxorubicin began to show
a survival benefit 17. That result could indicate that
an unexplained treatment effect occurred after dis-
ease progression. One possibility is that, because li-
posomal doxorubicin was available only on study at
the time, treatment crossover upon progression was
not possible for patients in the topotecan treatment
arm, but that patients in the liposomal doxorubicin
arm probably would have received subsequent
topotecan. The sequence of the chemotherapy deliv-
ery may perhaps account for the treatment effect;
however, with limited clinical benefit and no follow-
up data reported, the Gynecology Cancer DSG con-
cluded that further confirmation of the observed
results would be needed to support the superiority of
one agent over another in that trial. No other survival
differences were reported in the remaining nine
trials 14,16,18,19,21,23–26.
Five trials reported separate subgroup analyses of
survival results by platinum sensitivity 16–19,21. In the
platinum-sensitive subgroups, three trials 16,18,21 re-
ported no significant survival difference between treat-
ment groups; one trial 17 detected a survival advantage
with liposomal doxorubicin; and one trial 19 detected
a survival advantage with topotecan. Gordon et al. 17
reported a significant survival advantage for pegylated
doxorubicin over topotecan (27 months vs. 18 months,
p = 0.017). That 9-month survival benefit seems prom-
ising, but it is based on a subgroup analysis and, again,
the Gynecology Cancer DSG concluded that further
confirmation of those results would be needed to es-
tablish the superiority of liposomal doxorubicin overPRACTICE GUIDELINE SERIES
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TABLE II Response rates and survival outcomes
Reference Patients Treatment Platinum- Response and survival outcomes a
(n) group sensitive (%) Response (%) Survival (mo.)
(³6 mo.) CR OR (PR+CR) PFS Median
Pfisterer et al., 2005 14 178 Carboplatin 100 6 31 6 17
NCIC OV15 178 Carboplatin/ 100 15 47 9 18
gemcitabine p<0.01 p<0.01
HR=0.72
(0.58–0.90)
Gonzalez–Martin et al., 2005 15 40 Carboplatin 100 20 50 8 17
GEICO 41 Carboplatin/ 100 27 76 11 Not
paclitaxel reached
p=0.02 p=0.02 p=0.002
HR=0.54 HR=0.31
(0.32–0.92) (0.14–0.68)
Buda et al., 2004 16 106 Paclitaxel 25 20 b 47 b 61 4
GONO/IOR 106 Paclitaxel/ 27 15 b 37 b 61 2
epirubicin
Gordon et al., 2004 17 239 Pegylated 46 4 20 4 15
Doxil 30-49 doxorubicin
235 Topotecan 47 5 17 4 13
p=0.038
HR=1.23
(1.01–1.50)
ten Bokkel Huinink et al., 2004 18 114 Paclitaxel 48 3 13 3 12
ITSG 112 Topotecan 46 5 21 4 15
Meier et al., 2004 19 179 Treosulfan 64 NR NR 3 NR
AGO 178 Topotecan 66 NR NR 5 NR
p<0.001
Parmar et al., 2003 20 410 Carboplatin c 100 NR 54 b 92 4
ICON4/AGO 392 Carboplatin/ 100 NR 66 b 12 29
paclitaxel c p=0.0004 p=0.02
HR=0.76 HR=0.82
(0.66–0.89) (0.69–0.97)
O’Byrne et al., 2002 21 107 Pegylated 40 2 19 4 11
doxorubicin
107 Paclitaxel 37 6 23 5 13
Cantu et al., 2002 22 50 Paclitaxel 100 17 45 9 26
47 CAP 100 30 55 16 35
p=0.038 p=0.043
HR=0.60 HR=0.58
(0.37–0.97) (0.34–0.98)
Bolis et al., 2001 23 95 Carboplatin 100 35 55 ~15 ~23
95 Carboplatin/ 100 30 58 ~18 ~28
epirubicin
Piccart et al., 2000 24 41 Paclitaxel 24 0 17 3 9
45 Oxaliplatin 29 0 16 3 10
Torri et al., 2000 25 116 Paclitaxel £50 NR 54 8 14
118 Paclitaxel/ £50 NR 52 7 12
doxorubicin
Bolis et al., 1999 26 41 Paclitaxel 0 7 17 6 d ~9
40 Paclitaxel/ 0 13 34 10 d ~14
epirubicin
a Data are rounded and only statistically significant differences between treatment groups are shown in boldface.
b Based on evaluable patients.
c The authors reported that 24% of patients received chemotherapy other than carboplatin or paclitaxel and carboplatin.
d Median duration of response.
CR = complete response; OR = objective response; PR = partial response; PFS = progression-free survival; NCIC OV15 = National Cancer Insti-
tute of Canada OV15 trial; HR = hazard ratio; GEICO = Grupo Espanol de Investigacion en Cancer de Ovario; GONO/IOR = Gruppo Oncologico
Nord Ovest/Istituto Oncologico Romagnolo; Doxil 30-49 = Doxil Study 30-49; ITSG = International Topotecan Study Group; AGO =
Arbeitsgemeinschaft Gynaekologische Onkologie; ICON = International Collaborative Ovarian Neoplasm Group; NR = not reported; CAP =
cyclophosphamide/doxorubicin/cisplatin; ~ = approximate values extracted from survival curves.FUNG-KEE-FUNG et al.
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topotecan. In the trial reported by Meier et al. 19,
topotecan was more effective than treosulphan for
patients with platinum-sensitive disease (16 months
vs. 14 months, p = 0.0068).
For patients with platinum-refractory or platinum-
resistant disease, none of the trials detected any sta-
tistically significant survival advantage with one
chemotherapy agent over another.
4.4.2 Progression-Free Survival
Progression-free survival was reported in eleven of
the thirteen randomized trials 14–22,24,25 and was ex-
tracted from survival curves in one trial 23. The re-
maining trial reported median duration of response
as a primary outcome of interest 26. Progression-free
survival was reported to be the primary study end-
point in four of the thirteen randomized trials 14,17,18,21.
In four trials of 100% platinum-sensitive patients,
a significant survival advantage was detected with
combination platinum-containing chemotherapy as
compared with single-agent chemotherapy with
carboplatin 14,15,20 or paclitaxel 22. In one trial of non-
platinum-containing chemotherapy 19, topotecan was
superior to treosulphan by a span of approximately
2 months (5.4 months vs. 3.0 months, p < 0.001). No
other statistically significant differences in progres-
sion-free survival or in median duration of response 26
were reported in the remaining trials 16–18,21,24–26.
Five trials reported subgroup analyses for pro-
gression-free survival by patient sensitivity sta-
tus 16–19,21. Gordon et al. 17 reported a significant
advantage in progression-free survival with pegylated
doxorubicin over topotecan for patients with plati-
num-sensitive disease (6.7 months vs. 5.4 months, p =
0.037), but not for patients with platinum-resistant
disease. In the trial reported by Meier et al. 19, topote-
can was more effective than treosulphan for patients
both with platinum-sensitive disease (6.6 months vs.
5.2 months, p = 0.0179) and with platinum-resistant
disease (4.2 months vs. 2.2 months, p = 0.0279). In
the two foregoing trials, the clinical benefit of the
superior treatment did not exceed 2 months. In the
remaining three trials 16,18,21, no significant differences
were detected between treatment subgroups.
4.4.3 Tumour Response
Tumour response was reported to be a primary study
endpoint in six of the randomized trials 15,18,23–26. Two
of these randomized trials detected statistically sig-
nificant differences in overall response rate favouring
carboplatin-based combination chemotherapy over
single-agent carboplatin 14,15. The remaining trials
reported no significant differences in response rate
between treatment groups 16–26.
4.5 Adverse Events Associated with Chemotherapy
As Table III shows, data on adverse events varied with
the treatment regimen, and although reporting dif-
fered between the studies, adverse events correlated
with known toxicity profiles.
Ten trials reported statistically significant differ-
ences in adverse events by treatment group 14–18,
21–23,25,26. On average, severe adverse events, gener-
ally hematologic, were significantly associated with
combination chemotherapy in trials comparing a com-
bination regimen with single-agent chemotherapy.
The agents most commonly used were paclitaxel,
carboplatin, topotecan, and pegylated doxorubicin.
Adverse events associated with paclitaxel included
alopecia (any grade) in 62%–100% of patients, neu-
rotoxic effects (any grade) in 5%–42% of patients,
severe leucopenia in 4%–24% of patients, and se-
vere nausea and vomiting in 2%–6% of pa-
tients 16,18,21–22,24–26. Carboplatin was associated with
low rates of severe hematologic events (typically 15%
of patients or fewer), severe nausea and vomiting in
approximately 10% of patients or fewer, and any
grade of alopecia in 2%–25% of patients 14,15,20,23.
When compared with paclitaxel or pegylated doxo-
rubicin, topotecan was significantly associated with
increased severe hematologic toxicities, and some
grade of alopecia occurred in 49%–76% of pa-
tients 17,18. In the two trials that studied pegylated
doxorubicin, the adverse events associated with that
agent included any grade of palmar–plantar
erythrodysesthesia (PPE) in approximately one half
of patients and severe PPE in 23% (Gordon et al. 17)
and 16% (O’Byrne et al. 21) of patients. One trial 21
also reported a significant difference in severe sto-
matitis in patients treated with pegylated doxorubi-
cin as compared with those treated with paclitaxel
(10% vs. 1%, p = 0.03).
4.6 Quality of Life
Six trials reported data on QOL outcomes 14,15,17,18,20,24.
Overall, no statistically significant differences in QOL
outcome were detected between treatment groups in
any of these randomized trials.
Three trials reported results of subgroup analy-
ses on specific QOL outcomes 14,15,20. One trial 14 re-
ported that symptomatic patients who received
gemcitabine and carboplatin had improved global
QOL, including faster palliation of abdominal symp-
toms, than did patients treated with carboplatin alone.
Another trial 15, which reported very high (>85%)
non-compliance with questionnaire completion at 6
and 12 months, reported that the nausea and vomit-
ing subscale scores were significantly higher (p =
0.033) with carboplatin than with the combination
of carboplatin and paclitaxel. In the ICON4 trial 20,
the authors reported that, when the nausea and vom-
iting subscale was analyzed separately, QOL on that
subscale was significantly worse among women re-
ceiving single-agent chemotherapy than it was in
women receiving multiple-agent chemotherapy (p =
0.0014).PRACTICE GUIDELINE SERIES
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TABLE III Patients with grade 3 or 4 adverse events during chemotherapy
Reference Patients Treatment Adverse events (%)
(n) group Grade 3 or 4 All grades
Pfisterer et al., 2005 14 178 Carboplatin 8 NR 12 12 2 2 0 NR 52  a
NCIC OV15 178 Carboplatin/ 27 NR 70 35 4 3 2 NR 51 4  a
gemcitabine p<0.01 p<0.01 p<0.01 p<0.01
Gonzalez–Martin et al., 40 Carboplatin 15 3 10 13 0 10 3 b 8 b 0 b 18 b
2005 15
GEICO 38 Carboplatin/ 5 5 18 3 0 3 3 b 8 b 24 b 87 b
paclitaxel p<0.009 p=0.001
Buda et al., 2004 16 99 Paclitaxel 5 9 18 1 6 NR NR 14 c 69 d
GONO/IOR 99 Paclitaxel/ 3 19 37 1 11 NR NR 12 c 62 d
epirubicin p=0.01
Gordon et al., 2004 17 239 Pegylated 5 10 12 1 NR NR NR NR NR 16
Doxil 30-49 235 doxorubicin
Topotecan 28 50 77 34 NR NR NR NR NR 49
p<0.001 p<0.001 p<0.001 p<0.001 p=0.007
ten Bokkel Huinink et al., 114 Paclitaxel 6 21 52 3 2 3 1 d 0 d 16 93
2004 18
ITSG 112 Topotecan 41 85 95 50 10 10 6 d 5 d 17 6
p<0.01 p<0.01
Meier et al., 2004 19 179 Treosulfan 1 NR 52 NR NR NR NR NR NR
AGO 178 Topotecan 4 NR 47 7 NR NR NR NR NR NR
Parmar et al., 2003 20 410 Carboplatin 46 e 40 b NR NR 1 b 25 b 40 b
ICON4/AGO 392 Carboplatin/ 29 e 35 b NR NR 20 b 86 b 35 b
paclitaxel
O’Byrne et al., 2002 21 107 Pegylated 2 6 7 NR 79 NR NR 13 f 44
107 doxorubicin
Paclitaxel 4 8 13 NR 22 NR NR 42 f 88
p=0.002 p=0.002
Cantu et al., 2002 22 47 Paclitaxel NR 41 30 1 7  c NR NR 11 87
47 CAP NR 34 36 13 51 c NR NR 66 0
p=0.001 p=0.009 p=0.012 p=0.004 p=0.002 p=0.01
Bolis et al., 2001 23 95 Carboplatin 10 13 NR 20 3 NR NR NR 5 g
95 Carboplatin/ 25 53 NR 64 13 NR NR NR 88 g
epirubicin p<0.05 p<0.05 p<0.05 p<0.05 p<0.01
Piccart et al., 2000 24 41 Paclitaxel 2 NR 22 0 2 2 0 g NR 7 g NR
45 Oxaliplatin 2 NR 044 7 4 g NR 9 g NR
Torri et al., 2000 25 116 Paclitaxel NR 7 NR NR NR NR NR NR 19 c NR
118 Paclitaxel/ NR 24 NR NR NR NR NR NR 19 c NR
doxorubicin p<0.05
Bolis et al., 1999 26 41 Paclitaxel 12 24 NR 22 NR NR 15 c 100
40 Paclitaxel/ 30 45 NR 25 8 NR NR 5 c 100
epirubicin p=0.04 p=0.05 p=0.003
a Grade 2 toxicity.
b Grades 2–4 toxicity combined.
c Grades 2–3 toxicity combined.
d Grades 3–4 toxicity combined.
e Hematologic toxicity leading to treatment modification or interruption.
f Paresthesia.
g Grade 3 toxicity.
NCIC OV15 = National Cancer Institute of Canada OV15 trial; NR = not reported; GEICO = Grupo Espanol de Investigacion en Cancer de Ovario;
GONO/IOR = Gruppo Oncologico Nord Ovest/Istituto Oncologico Romagnolo; Doxil 30-49 = Doxil Study 30-49; ITSG = International Topotecan
Study Group; AGO = Arbeitsgemeinschaft Gynaekologische Onkologie; ICON = International Collaborative Ovarian Neoplasm Group; CAP =
cyclophosphamide/doxorubicin/cisplatin.
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5. DISCUSSION
The goals of therapy for patients with recurrent ova-
rian cancer are to improve QOL and extend survival.
Therefore, with regard to deriving conclusions based
on the available evidence, it was important to con-
sider the generalizability of the results, to assess the
methodologic quality of the studies forming the evi-
dentiary base, and to interpret the results in a clini-
cally meaningful manner.
Even though the literature search uncovered thir-
teen RCTs that investigated the role of chemotherapy
in patients with recurrent ovarian cancer and prior
platinum exposure, the data are incomplete. Although
platinum sensitivity status is more of a continuum
than a discrete event, it has an impact on patient out-
comes—an impact supported by the current body of
evidence. Only six of the thirteen trials included solely
patients who were considered either 100% platinum-
sensitive 14,15,20,22,23 or 100% platinum-resistant 26. A
further five trials reported subgroup analyses by plati-
num sensitivity 16–19,21, but those studies were not de-
signed to compare differences between subgroups,
and their results must therefore be interpreted with
caution.
In addition, study size, characteristics, and de-
sign must also be considered when interpreting the
data. Eight trials provided power calculations, but four
trials randomized fewer than 50 patients per arm; five
trials included approximately 100 patients per arm;
and the four larger studies randomized at least 150 pa-
tients per arm. Unsurprisingly, most of statistically
significant results stemmed from the larger random-
ized trials. The characteristics of the trials varied
widely, exhibiting important differences in chemo-
therapy regimens such as platinum versus non-plati-
num-containing regimens, single-agent versus
combination chemotherapy, and varying lengths in
the planned chemotherapy cycles, making it difficult
to compare results across trials. In addition, the pri-
mary study endpoints also varied widely across the
trials. These endpoints were roughly divided by re-
sponse rate 15,18,23–26, progression-free survival 14,17,
18,21, and overall survival 16,17,19–22.
Despite the noted differences among the identi-
fied trials, the methodologic quality of the individual
trials was reasonably high, with most trials reporting
(but not statistically comparing) well-balanced base-
line patient characteristics, completeness of follow-
up greater than 80%, power and patient accrual
sufficient to detect statistically significant differences
between treatment groups, and the intent-to-treat prin-
ciple. These trials were generally multicentric inves-
tigations that took place in the phase III setting.
Overall, for patients with platinum-sensitive re-
current disease, evidence from four trials 14,15,20,22 is
sufficient to conclude that platinum-containing com-
bination chemotherapy improves response and sur-
vival outcomes as compared with single-agent
carboplatin or paclitaxel. The more compelling evi-
dence comes from one large trial 20 and one small
supporting trial 15 that compared the combination of
carboplatin and paclitaxel with single-agent carbo-
platin. The combination of gemcitabine and carbo-
platin also improved response and progression-free
survival as compared with carboplatin alone 14. In the
single-agent setting, carboplatin was not as effica-
cious as combination chemotherapy, but it still
showed consistent efficacy across trials with a man-
ageable toxicity profile. As part of non-platinum-con-
taining chemotherapy, paclitaxel, topotecan, and
liposomal doxorubicin showed activity in patients
with platinum-sensitive disease 17,18,21; however, none
of those agents has been compared in the random-
ized setting against platinum-based chemotherapy. In
that setting, given the unexpected findings, subgroup
analyses, and mixed results across trials, establish-
ing the superiority of one non-platinum agent over
another is difficult without further confirmation of
results.
For patients with platinum-refractory or -resis-
tant disease, the non-platinum-containing combina-
tion chemotherapy in three trials was no more
efficacious than was the non-platinum single-agent
chemotherapy; however, in terms of the number of
trials, number of patients studied, and number of regi-
mens investigated, the data are limited.
In five trials, non-platinum single-agent treatment
options included paclitaxel, topotecan, liposomal
doxorubicin, or treosulphan. One trial 17 reported a
2-month statistically significant difference in median
survival with liposomal doxorubicin in a mixed plati-
num-sensitive patient population; however, the lim-
ited clinical benefit, coupled with unexpected
findings, subgroup analyses, and a lack of confirma-
tion of results leads to a conclusion of uncertain su-
periority for the agents being compared. On the basis
of one trial 19, topotecan appears to be more effective
than treosulphan in extending progression-free sur-
vival, but that result does little to inform the clinical
scenario in the context of current clinical practice. It
should be noted that the survival benefit of any one
chemotherapy agent over another did not exceed
3 months in any of the randomized trials.
Thus, for patients with platinum-refractory or
-resistant disease, the data provide little definitive
comment on the efficacy of combination chemo-
therapy as compared with single-agent chemotherapy
or on the efficacy of any single agent over another.
6. CONCLUSIONS
Given the available data, it would seem reasonable
to conclude that, as long as patients continue to re-
spond to platinum-based chemotherapy with no
contraindications, then combination platinum-based
chemotherapy should be considered for this patient
population. This conclusion is based on the improvedPRACTICE GUIDELINE SERIES
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survival benefits, but recognizes the increase in ad-
verse events.
If combination therapy is not indicated (because
of toxicity or otherwise), then a single platinum agent
should be considered if indicated. Single-agent
carboplatin has been effective in this patient popula-
tion, and it has a manageable toxicity profile. Patients
could continue to receive platinum-based chemo-
therapy across multiple lines, if need be, for as long
as they remain sensitive to platinum-containing
chemotherapy.
If platinum-containing chemotherapy is not being
considered, then monotherapy with a non-platinum
agent should be considered on the basis of patient
preference, toxicity profile, ease of administration,
and availability. Single-agent paclitaxel, topotecan,
or pegylated liposomal doxorubicin have demon-
strated activity in this patient population and are rea-
sonable treatment options.
For patients who do not respond to platinum-
based chemotherapy, then treatment decisions should
be based on patient preference, toxicity profile, ease
of administration, and availability. The use of com-
bination chemotherapy does not appear to be advan-
tageous in this group of patients, and no evidence
either supports or refutes the use of multiple lines of
chemotherapy in patients with platinum-resistant re-
currences. Single-agent paclitaxel, topotecan, or
pegylated liposomal doxorubicin have demonstrated
activity in this patient population and are reasonable
treatment options.
Platinum-sensitivity status in these patients
should be regarded as a continuum rather than a dis-
crete outcome. It is therefore recognized that each
patient needs to be individually assessed to deter-
mine optimal therapy in terms of recurrence, sensi-
tivity to platinum, toxicity, ease of administration,
and patient preference. Participation in randomized
trials should be encouraged for all patients, where
appropriate.
Further research from randomized trials is needed
to determine the optimum chemotherapeutic regimen
for patients with both platinum-sensitive and plati-
num-resistant recurrent ovarian cancer. The roles of
further cytoreductive surgery and carboplatin desen-
sitizing agents remain to be determined. Currently,
studies planned or underway include the Southwest
Oncology Group S0200 phase III trial of carboplatin
with or without pegylated doxorubicin in platinum-
sensitive disease, the CALYPSO study (a Gynaecologic
Cancer Intergroup study) of carboplatin and paclitaxel
versus carboplatin and liposomal doxorubicin in plati-
num-sensitive recurrence, and another Intergroup
study (ICON6, led by the U.K. Medical Research Coun-
cil) in patients with platinum-sensitive disease, which
will explore the addition of a targeted molecular agent
(AZD2171, against vascular endothelial growth fac-
tor) to carboplatin and paclitaxel therapy. The results
of ongoing trials should help to determine the most
appropriate treatment options for patients with recur-
rent epithelial ovarian cancer.
7. INTERNAL REVIEW OF THE PRACTICE
GUIDELINE REPORT
7.1 RAP Feedback
Before external review, the draft report was reviewed
by the PEBC RAP, which consists of 2 members, in-
cluding an oncologist with expertise in clinical and
methodology issues.
One major issue raised by the RAP was that the
link between the evidence and the recommendations
for platinum-resistant or -refractory patients was con-
fusing to follow. The RAP commented that although
two trials appeared to show differences in survival,
the relevant information did not appear to factor into
the formulation of the practice recommendation. Re-
lated to this issue was the comment that greater dis-
cussion was required concerning the DSG’s
interpretation of results from one trial in which
methodologic issues were raised about the crossing
of survival curves, but in which was also detected a
significant survival difference between treatment
groups. The RAP commented that the DSG had not ad-
equately justified its statement regarding the
methodologic concerns potentially affecting the sur-
vival outcomes in that trial.
As part of minor comments, suggestions about
the structure and format of the report were also of-
fered. The RAP found that the text-dense format of
the Trial Characteristics and Trial Quality sections
made it difficult for readers to link the various ele-
ments and to interpret the findings in a meaningful
manner. One RAP member felt that use of subhead-
ings could be helpful, and one suggested that the in-
formation might be better presented in tables.
As a final comment, the RAP noted that a refer-
ence in the Introduction to the case fatality ratio was
unclear about whether that value came from a sepa-
rate reference or was calculated from the incidence
and mortality data presented in the same sentence.
The RAP suggested that the DSG reword or clarify.
7.2 Modifications
In response to the RAP’s comments, the Gynecology
Cancer DSG addressed the presentation of the link
between the evidence and the recommendations in
the Survival, Discussion, and Key Evidence sections.
The primary issue was that results from the trial by
Gordon et al., which detected an overall 2-month
survival benefit with pegylated doxorubicin over
topotecan was not reflected in the recommendations
where liposomal doxorubicin, topotecan, and pacli-
taxel were all listed as reasonable treatment options.
The findings from that trial were unexpected, because
no significant differences in response rate or progres-FUNG-KEE-FUNG et al.
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sion-free survival had been detected between the treat-
ment arms, and the survival curves for the treatment
arms were virtually indistinguishable for approxi-
mately the first year. The trial then went on to show a
2-month survival benefit shortly beyond year 1 that
was even more pronounced in the subgroup analysis
of platinum-sensitive patients (9-month improvement
in median survival).
The Survival section hypothesized that a treat-
ment effect may have occurred after disease pro-
gression, one possibility being that, because
liposomal doxorubicin was available only on study
at the time, treatment crossover upon progression
was not possible for patients in the topotecan treat-
ment arm, but patients in the liposomal doxorubicin
arm were likely to have received subsequent
topotecan. Perhaps the sequence of the chemo-
therapy delivery can account for the treatment ef-
fect. However, with the unexpected findings, the
limited clinical benefit outside of subgroup analy-
sis, and no follow-up data reported, that trial would
need further confirmation of results before the Gy-
necology Cancer DSG could conclude superiority of
one agent over another.
In the second trial in which the superiority of
topotecan over treosulphan in progression-free sur-
vival was detected, the results from that trial did
little to inform the clinical picture, given that
treosulphan was not being recommended as one of
the three single agents being considered as reason-
able treatment options. Potentially confusing sub-
group results from that trial were removed from
Table II, and the description of the results was re-
vised to improved clarity.
To improve clarity in the Results section, sum-
mary sentences were added to the Trial Character-
istics and Trial Quality subsections: one sentence
provides an overall assessment of the relative ho-
mogeneity or heterogeneity of the identified trials,
and the other comments on external validity through
an assessment of the internal validity of the trials.
The text in these sections was also divided into
smaller paragraphs to improve readability.
Finally, where the Introduction referred to the
potentially confusing case fatality ratio, the wording
was changed to a ratio of mortality to incidence.
8. EXTERNAL REVIEW OF THE PRACTICE
GUIDELINE REPORT
8.1 Practitioner Feedback Survey
The systematic review and practice guideline were
distributed for review and feedback to practitioners
throughout Ontario, Canada, in accordance with the
practice guidelines development cycle 12. A sample
of 170 practitioners in Ontario received the survey,
which consisted of items evaluating the methods, re-
sults, and interpretive summary used to inform the
draft recommendations and of questions about
whether the draft recommendations should be ap-
proved as a practice guideline. Written comments
were invited. The practitioner feedback survey was
mailed on September 18, 2006, and a complete re-
peat mailing was sent thereafter. The Gynecology
Cancer DSG reviewed the results of the survey.
8.2 Survey Results
From among the 170 surveys sent, 85 responses were
received. Responses include returned completed sur-
veys, plus telephone, fax, and e-mail responses. Of
the practitioners who responded, 22 indicated that
the report was relevant to their clinical practice, and
they completed the survey. Table IV summarizes key
results.
Of the respondents, 7 provided written comments.
In general, the comments were highly positive and
accorded with the conclusions derived by the Gyne-
cology Cancer DSG. Five practitioners commented
favourably on the quality and development of the
series overall, although one practitioner asked why
the DSG would undertake a guideline given the level
of evidence available for analysis. One practitioner
commented that highly motivated patients with plati-
num-resistant disease often receive more than one
line of chemotherapy. One practitioner suggested that
a comment be added about treatment in platinum-
sensitive patients after third-line chemotherapy. Two
practitioners commented that addressing related top-
ics such as carboplatin desensitization or further
cytoreductive surgery would be helpful.
8.3 Action Taken
On the basis of the survey results, which were sup-
portive of the guideline, the Gynecology Cancer DSG
concluded that no substantive revisions to the docu-
ment were needed.
The comment regarding the body of evidence in
this treatment setting makes a valid point. However,
the Gynecology Cancer DSG agreed that that it was
possible and necessary to derive meaningful conclu-
sions from the available randomized evidence. The
need for further research on this topic area is well
recognized. The authors also recognize that the ideal
number of regimens is not well informed by the evi-
dence, but strategies for the management of recur-
rent ovarian cancer is the focus of another guideline
in development by the Gynecology Cancer DSG. The
impact of related issues such as further cytoreductive
surgery and the use of carboplatin desensitizing agents
are of interest, but are not a focus of the present re-
port. A sentence regarding future research in these
areas was added.
The present report reflects the integration of the
feedback obtained through the external review pro-
cess with the final approval given by the RAP and thePRACTICE GUIDELINE SERIES
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Gynecology Cancer DSG. Updates of the report will
be issued as new evidence informing the question of
interest emerges.
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